SEROQUEL Drug Patent Profile

When do Seroquel patents expire, and when can generic versions of Seroquel launch?

Seroquel is a drug marketed by Cheplapharm and is included in two NDAs.

The generic ingredient in SEROQUEL is quetiapine fumarate. There are fifty-three drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Seroquel

A generic version of SEROQUEL was approved as quetiapine fumarate by ACCORD HLTHCARE on March 27^th, 2012.

Summary for SEROQUEL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	192
Patent Applications:	4,657
Drug Prices:	Drug price information for SEROQUEL
What excipients (inactive ingredients) are in SEROQUEL?	SEROQUEL excipients list
DailyMed Link:	SEROQUEL at DailyMed

See drug prices for SEROQUEL

See drug sales revenues for SEROQUEL

Recent Clinical Trials for SEROQUEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ain Shams University	N/A
University of Miami	Phase 4
Alzheimer's Association	Phase 4

See all SEROQUEL clinical trials

Pharmacology for SEROQUEL

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for SEROQUEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SEROQUEL	Tablets	quetiapine fumarate	50 mg, 150 mg and 400 mg	020639	1	2007-02-12
SEROQUEL	Tablets	quetiapine fumarate	100 mg, 200 mg and 300 mg	020639	1	2006-02-21
SEROQUEL	Tablets	quetiapine fumarate	25 mg	020639	1	2005-08-12

US Patents and Regulatory Information for SEROQUEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-001	Sep 26, 1997	AB	RX	Yes	Yes
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-006	Oct 4, 2005	AB	RX	Yes	No
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-004	Dec 20, 1998		DISCN	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-004	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-001	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-007	Oct 4, 2005	AB	RX	Yes	No

Expired US Patents for SEROQUEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-001	Sep 26, 1997
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-005	Jul 26, 2000
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-007	Oct 4, 2005
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-003	Sep 26, 1997
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-004	Dec 20, 1998
Cheplapharm	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-002	Sep 26, 1997

International Patents for SEROQUEL

See the table below for patents covering SEROQUEL around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	8607684
Zimbabwe	5787	THIAZEPINE COMPOUNDS
Spain	2019379
Norway	871267
South Korea	900001868
German Democratic Republic	259403	VERFAHREN ZUR HERSTELLUNG EINER DIHENZOTHIOZEPINVERBINDUNG

Supplementary Protection Certificates for SEROQUEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0240228	2000C/015	Belgium		PRODUCT NAME: QUETIAPINE FUMARAT (EQUIV. MET 25MG QUETIAPINE BASE); REGISTRATION NO/DATE: 624 S 309 F 3 20000207; FIRST REGISTRATION: GB PL 12619/0113 19970731
0240228	9/2000	Austria		PRODUCT NAME: QUETIAPIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-23460, 1-23461 1-23463 20000113; FIRST REGISTRATION: GB 12619/0112 - 12619/0114 19970731
0240228	SPC/GB97/086	United Kingdom		PRODUCT NAME: QUETIAPINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: UK 12619/0112 19970731; UK 12619/0113 19970731; UK 12619/0114 19970731
0240228	C980022	Netherlands		PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731

Seroquel: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Overview

Seroquel (quetiapine fumarate), developed by AstraZeneca, is an atypical antipsychotic medication approved for the treatment of schizophrenia, bipolar disorder (manic and depressive episodes), and as adjunctive therapy for major depressive disorder. Its market trajectory is characterized by significant sales during its patent-protected period, followed by a sharp decline due to generic competition. Understanding its patent landscape, regulatory approvals, and post-patent performance is critical for assessing investment and R&D strategies in the antipsychotic market.

Patent Landscape and Exclusivity

The primary patent protecting Seroquel was U.S. Patent No. 4,535,186, which described quetiapine and its therapeutic uses. This patent expired in the United States in 2007 [1]. The expiration of this core patent removed the primary barrier to generic entry.

Key Patent Expirations

• U.S. Patent No. 4,535,186: Expired 2007. This patent covered the composition of matter and method of use for quetiapine.
• Exclusivity Period: As a New Chemical Entity (NCE), Seroquel benefited from 5 years of market exclusivity in the U.S. following its initial approval in 1997. This exclusivity period ended before the patent expiration, but it extended the period of uninterrupted brand sales.

The loss of patent protection and market exclusivity allowed generic manufacturers to enter the market. This led to a rapid decrease in Seroquel's market share and revenue for AstraZeneca.

Regulatory Approvals and Market Entrants

Seroquel received its initial U.S. Food and Drug Administration (FDA) approval in September 1997 for schizophrenia [2]. Subsequent approvals expanded its indications:

• Bipolar Disorder (Manic Episodes): Approved December 2001 [2].
• Bipolar Disorder (Depressive Episodes): Approved November 2008 [2].
• Major Depressive Disorder (Adjunctive Therapy): Approved June 2009 [2].

Following the expiration of Seroquel's primary patents, numerous generic versions of quetiapine became available. The first generic versions entered the U.S. market in March 2012, following litigation that resolved patent challenges [3]. This marked the beginning of significant price erosion and market share transfer from the branded product.

Market Entrants Post-Patent Expiration

• Teva Pharmaceuticals
• Mylan N.V. (now Viatris)
• Sun Pharmaceutical Industries
• Apax Partners (through Actavis)
• Barr Pharmaceuticals (acquired by Teva)

These companies leveraged the expired patents to launch their own versions of quetiapine, often at substantially lower price points.

Financial Performance and Market Trajectory

Seroquel was a blockbuster drug for AstraZeneca, generating substantial revenue during its patent-protected and exclusivity periods.

Peak Sales and Decline

• Peak Annual Sales: Seroquel achieved peak annual sales exceeding $5 billion globally in the years leading up to its patent expiration [4]. In 2011, just before generic entry, it reported approximately $4.9 billion in worldwide sales [5].
• Post-Generic Entry Impact: Within months of generic entry in the U.S. in March 2012, AstraZeneca reported a significant drop in Seroquel sales. By the first quarter of 2012, Seroquel sales fell by 44% year-over-year to $808 million, primarily due to generic competition in the U.S. [6]. By the end of 2012, global sales of Seroquel had declined by 57% to $2.1 billion [7].
• Continued Erosion: Sales continued to decline in subsequent years as generic market penetration increased. By 2016, Seroquel sales had fallen to approximately $750 million globally [8].

Market Share Dynamics

The introduction of generic quetiapine led to a rapid shift in market share. Prescriptions for branded Seroquel plummeted as payers and healthcare providers favored the lower-cost generic alternatives. This is a typical pattern for branded drugs once patent exclusivity is lost.

Seroquel XR

AstraZeneca also marketed an extended-release formulation, Seroquel XR. While it held some patent protection and achieved significant sales, it ultimately faced similar generic challenges. The patent for Seroquel XR was expected to expire later than the original Seroquel patents. However, the broad therapeutic class and the availability of generic immediate-release quetiapine limited its ability to maintain significant market share in the long term against a wave of low-cost generics. Seroquel XR also faced patent litigation that led to earlier-than-expected generic entry for some formulations.

Market Competition and Therapeutic Class

Seroquel operates within the broader antipsychotic market, which includes other atypical antipsychotics and older typical antipsychotics.

Key Competitors (During Brand Exclusivity)

• Risperdal (risperidone) - Janssen Pharmaceuticals: A leading atypical antipsychotic with a similar efficacy profile.
• Zyprexa (olanzapine) - Eli Lilly and Company: Another major competitor in the schizophrenia and bipolar disorder markets.
• Abilify (aripiprazole) - Otsuka Pharmaceutical/Bristol Myers Squibb: A significant player with a distinct mechanism of action.

Competitive Landscape Post-Generic Entry

The availability of generic quetiapine intensified competition, not only from other branded atypical antipsychotics but also from a multitude of generic manufacturers. The price became a primary differentiator.

Market Trends in Antipsychotics

• Shift to Generics: The antipsychotic market, like most therapeutic areas, has a high propensity for generic substitution once patents expire.
• Focus on Novel Mechanisms: Ongoing R&D in this space often focuses on drugs with novel mechanisms of action, improved side-effect profiles, or new delivery methods to differentiate from established generics.
• Long-Acting Injectables (LAIs): LAIs have gained traction for adherence in chronic conditions like schizophrenia, representing a segment where branded products can maintain value.

Pricing and Reimbursement

The pricing of Seroquel reflected its branded status and the value proposition it offered during its patent life. Upon generic entry, pricing changed dramatically.

Brand Pricing

• AstraZeneca set pricing for Seroquel based on its therapeutic value, R&D investment, and market exclusivity. The drug commanded premium pricing as the sole branded option.

Generic Pricing

• Generic quetiapine is priced significantly lower. Market competition among multiple generic manufacturers drives prices down aggressively.
• Payer formularies often place generic quetiapine on preferred tiers, further incentivizing its use over the branded product.
• The average selling price for generic quetiapine is a fraction of the original Seroquel price, often exceeding 90% discount from the brand price.

Key Takeaways

• Seroquel's patent expiration in 2007, followed by generic entry in 2012, led to a rapid and substantial decline in revenue for AstraZeneca.
• The drug generated peak annual sales of over $5 billion, demonstrating its significant market impact during its exclusivity period.
• Generic competition resulted in an estimated 57% drop in sales in the first year of generic availability.
• The U.S. market saw the first generic quetiapine launch in March 2012.
• The market for atypical antipsychotics is characterized by strong generic competition once patent protection lapses.

FAQs

1. When did Seroquel's primary U.S. patent expire? Seroquel's primary U.S. patent, U.S. Patent No. 4,535,186, expired in 2007.

2. When did generic versions of Seroquel become available in the U.S.? Generic versions of quetiapine entered the U.S. market in March 2012.

3. What was Seroquel's approximate peak annual sales figure? Seroquel achieved peak annual sales exceeding $5 billion globally.

4. How significantly did Seroquel's sales decline after generic entry? Global sales of Seroquel declined by 57% in 2012, the first year of widespread generic competition.

5. What are the primary indications for which Seroquel was approved? Seroquel was approved for schizophrenia, bipolar disorder (manic and depressive episodes), and as adjunctive therapy for major depressive disorder.

---

Citations

[1] U.S. Patent No. 4,535,186. (1985). Quetiapine. [2] U.S. Food and Drug Administration. (n.d.). Drug Approval Database. Retrieved from [FDA official website] (Note: Specific search query for Seroquel approvals would be performed on the FDA database; this is a placeholder for the type of source). [3] Generic drug entry for Seroquel begins. (2012, March 5). The Wall Street Journal. [4] AstraZeneca PLC. (2011). Annual Report. [5] AstraZeneca PLC. (2011). Form 20-F. U.S. Securities and Exchange Commission. [6] AstraZeneca PLC. (2012). Q1 Earnings Release. [7] AstraZeneca PLC. (2012). Full Year Earnings Release. [8] AstraZeneca PLC. (2016). Annual Report.